Radioiodination, purification and bioevaluation of Piroxicam in comparison with Meloxicam for imaging of inflammation

被引:8
作者
Amin, A. M. [1 ]
Gouda, A. A. [2 ]
El-Sheikh, R. [2 ]
Seddik, U. [3 ]
Hussien, H. [3 ]
机构
[1] Atom Energy Author, Hot Labs Ctr, Labeled Compound Dept, Cairo, Egypt
[2] Zagazig Univ, Fac Sci, Dept Chem, Zagazig, Egypt
[3] Atom Energy Author, Nucl Res Ctr, Cyclotron Project, Cairo, Egypt
关键词
EXCHANGE; PROTEIN;
D O I
10.1007/s10967-009-7483-9
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
The present study is performed to compare the electrophilic substitution radioiodination reaction of two non-steroidal anti-inflammatory drugs namely, Piroxicam (Pirox) and Meloxicam (Melox) with I-125 where both chloramine-T (CAT) and iodogen were used as oxidizing agents. The factors affecting the percent of radiochemical yields such as drug concentration, pH of the reaction mixtures, different oxidizing agents, reaction time, temperature and different organic media were studied to optimize the conditions for labeling of Pirox and Melox and to obtain high radiochemical yields. The maximum radiochemical yield of I-125-Piroxicam (I-125-Pirox) was 94% using 3.7 MBq of (NaI)-I-125, 0.4 mM of Pirox as substrate, 3.6 mM of chloramine-T (CAT) as oxidizing agent in acetone at neutral pH = 7 and at 60 A degrees C within 20 min where the maximum radiochemical yield of I-125-Melox was 92% using 0.7 mM of Melox as substrate, 0.62 mM of iodogen as oxidizing agent in acetone at neutral pH = 7 and at 25 A degrees C within 30 min. The radiochemical yields were determined by TLC and high-pressure liquid chromatography (HPLC). Tracers showed good localization in inflamed muscle either septic or sterile. The collected data indicates that Pirox and Melox can be used as antiinflammatory imaging agents at 24 and 2 h post injection, respectively.
引用
收藏
页码:589 / 598
页数:10
相关论文
共 17 条
[1]   THE MECHANISMS OF ACTION OF NONSTEROIDAL ANTIINFLAMMATORY DRUGS [J].
ABRAMSON, SB ;
WEISSMANN, G .
ARTHRITIS AND RHEUMATISM, 1989, 32 (01) :1-9
[2]  
Arayne M Saeed, 2005, Pak J Pharm Sci, V18, P58
[3]  
BAERER FC, 1979, J MOL PHARMACOL, V12, P328
[4]  
BUSCH U, 1998, AM SOC PHARM EXPT TH, P26
[5]  
El-Azony K. M., 2004, ARAB J NUCL SCI APPL, V37, P81
[6]  
El-Sheikh R, 2007, ARAB J NUCL SCI APPL, V40, P36
[7]  
ELGHANY EA, 2005, J RADIOANAL NUCL CHE, V125, P266
[8]  
ELGHANY EA, 2005, J RADIOANAL NUCL CHE, V117, P266
[9]  
FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0
[10]  
Hardman J.G., 1996, PHARM BASIS THERAPEU